Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 5, Status: Authorised

Development and manufacture of synthetic peptides - Scientific guideline

Parallel scientific advice and special development aspects or product types

Human medicines European public assessment report (EPAR): Ezmekly, mirdametinib, Date of authorisation: 17/07/2025, Revision: 2, Status: Authorised

Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices

Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Evrenzo, roxadustat, Date of authorisation: 18/08/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Olazax Disperzi, olanzapine, Date of authorisation: 10/12/2009, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Zoledronic acid Actavis, zoledronic acid, Date of authorisation: 20/04/2012, Revision: 16, Status: Withdrawn

EMA actively monitoring cruise ship Hantavirus outbreak